Kymera Therapeutics (KYMR) Leases (2019 - 2025)
Historic Leases for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $42.9 million.
- Kymera Therapeutics' Leases fell 1064.81% to $42.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.9 million, marking a year-over-year decrease of 1064.81%. This contributed to the annual value of $47.4 million for FY2024, which is 1045.99% down from last year.
- As of Q3 2025, Kymera Therapeutics' Leases stood at $42.9 million, which was down 1064.81% from $46.0 million recorded in Q2 2025.
- Over the past 5 years, Kymera Therapeutics' Leases peaked at $56.6 million during Q1 2023, and registered a low of $8.9 million during Q4 2022.
- Moreover, its 5-year median value for Leases was $46.0 million (2025), whereas its average is $32.9 million.
- Per our database at Business Quant, Kymera Therapeutics' Leases surged by 50818.74% in 2023 and then tumbled by 1285.24% in 2024.
- Quarter analysis of 5 years shows Kymera Therapeutics' Leases stood at $9.4 million in 2021, then fell by 5.48% to $8.9 million in 2022, then skyrocketed by 494.29% to $52.9 million in 2023, then dropped by 10.46% to $47.4 million in 2024, then fell by 9.41% to $42.9 million in 2025.
- Its last three reported values are $42.9 million in Q3 2025, $46.0 million for Q2 2025, and $46.7 million during Q1 2025.